Korsana Biosciences/$KRSA

1D1W1MYTD1Y5YMAX

About Korsana Biosciences

Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
Ticker
$KRSA
Sector
Health
Primary listing
NASDAQ
Employees
19
Headquarters
Waltham, United States
Website
korsana.com

KRSA Metrics

BasicAdvanced
$1.6B
-
-$13.37
-
-

Bulls say / Bears say

The $380 million private financing and roughly $475 million of post-transaction cash are expected to fund operations into 2029. That gives Korsana scope to reach several clinical milestones without an immediate need to raise more capital. (Yahoo Finance, Markets Insider)
KRSA-028 is designed to combine TfR1 brain shuttling with Fc engineering, potentially increasing brain exposure while reducing ARIA and enabling a low-volume subcutaneous injection. If those design goals translate into human data, the product could address important convenience and tolerability weaknesses of current anti-amyloid therapies. (Korsana Biosciences, AllSci)
The underlying delivery approach has attracted substantial pharmaceutical interest, including Roche’s Phase 3 trontinemab programme and recent large transactions involving similar TfR1-based technology. That external validation could improve Korsana’s partnering or strategic-exit potential if KRSA-028 produces convincing data. (AllSci, Fierce Biotech)
KRSA-028 is still in IND-enabling work, with healthy-volunteer data not expected until mid-2027 and Alzheimer’s patient proof-of-concept data only around late 2027 or early 2028. Investors therefore face a long period in which the drug’s safety, brain delivery and efficacy remain untested in humans. (AInvest, Korsana Biosciences)
The blood-brain-barrier shuttle field is becoming crowded. Roche is advancing trontinemab into Phase 3, while AbbVie has bought a similar asset and existing anti-amyloid drugs already compete for patients and prescriber attention. (Fierce Biotech, Citeline)
The investment case is highly concentrated in KRSA-028: the other THETA-enabled programmes are undisclosed and remain in discovery. A delay, safety problem or weak result for the lead antibody would therefore leave little near-term pipeline support for the valuation. (SEC.gov, Fierce Biotech)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.